Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RU486: a compound that gets itself talked about

E E Baulieu1

  • 1Institut National de la Santé et de la Recherche Médicale, Unité 33, Le Kremlin-Bicêtre, France.

Human Reproduction (Oxford, England)
|June 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stimulation of transcription in vitro from a liver-specific promoter by human glucocorticoid receptor (hGRalpha).

The Biochemical journal·1997
Same author

Hydroxysteroid sulfotransferase activity in the rat brain and liver as a function of age and sex.

Steroids·1997
Same author

Metabolism of 27-, 25- and 24-hydroxycholesterol in rat glial cells and neurons.

The Biochemical journal·1997
Same author

RU486 (mifepristone): mechanisms of action and clinical uses.

Annual review of medicine·1997
Same author

FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin.

The Journal of biological chemistry·1996
Same author

Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study.

Proceedings of the National Academy of Sciences of the United States of America·1996

Mifepristone (RU486) offers a safe, oral option for medical abortion, potentially reducing unsafe procedures. Its combination with prostaglandins is a significant advancement in reproductive health, though political factors may delay access.

Area of Science:

  • Reproductive Medicine
  • Pharmacology

Background:

  • Medical abortion remains a critical aspect of reproductive healthcare globally.
  • Unsafe abortions pose significant risks, particularly in regions with limited access to safe options.
  • Mifepristone (RU486) has been a subject of extensive research and public debate regarding its use.

Purpose of the Study:

  • To highlight the significance of mifepristone (RU486) in medical abortion.
  • To discuss the potential of combining mifepristone with prostaglandins for pregnancy termination.
  • To address the challenges and delays in the introduction and widespread use of mifepristone.

Main Methods:

  • Review of existing literature on mifepristone and prostaglandin combinations for medical abortion.
  • Analysis of the socio-political factors influencing the accessibility of mifepristone.
Keywords:
Abortifacient AgentsAbortion LawAbortion, Drug InducedAbortion, InducedBiologyContraceptionCritiqueDeveloped CountriesEndocrine SystemEuropeFamily PlanningFertility Control, PostconceptionFranceHormone AntagonistsHormonesLegislationMediterranean CountriesPhysiologyPolitical FactorsRu-486Western Europe

Related Experiment Videos

  • Discussion of the drug's potential therapeutic applications beyond abortion.

    • Main Results:

    • The combination of mifepristone (RU486) and an oral prostaglandin provides a safe and effective method for terminating early pregnancy.
    • This combination has the potential to mitigate the risks associated with unsafe abortion procedures.
    • The drug's broader therapeutic potential for various diseases is also noted.

    Conclusions:

    • Mifepristone, particularly in combination with prostaglandins, represents a crucial advancement in reproductive healthcare, offering a safe alternative to surgical abortion.
    • The accessibility of this medical abortion method is hindered by political and regulatory challenges, impacting women's health, especially in developing nations.
    • Further research and policy changes are needed to ensure equitable access to mifepristone for both reproductive health and other potential medical treatments.